The BioHub - by Avetix Episode 100 - Lance Baldo - CEO of Beacon Therapeutics
10 snips
Dec 16, 2025 
Lance Baldo, CEO of Beacon Therapeutics and seasoned biotech executive, shares insights from his impressive career in ophthalmology. He discusses the VISTA phase-3 trial of laru-zova, an AAV gene therapy for X-Linked Retinitis Pigmentosa, detailing its promising progress and expected results in 2026. Lance delves into the challenges of transitioning to CEO, and emphasizes the importance of team dynamics and regulatory strategies. His journey from medicine to biotech highlights his commitment to innovation and patient impact in treating blinding diseases.
AI Snips
Chapters
Transcript
Episode notes
From Surgery Trainee To Pharma Founder
- Lance left surgical training to start a medical software company and then moved into pharmaceuticals after raising venture capital.
- He credits that founder experience and mentorship (notably Clive) for shaping his commercial career path into pharma leadership.
Pick Roles That Match Your Sweet Spot
- Join opportunities that match your functional sweet spot instead of every exciting project.
- Lance chose Beacon because it fit his late-stage development and commercialization strength.
Larizova Phase 3 Nearing Readout
- Beacon's lead program larizova is an AAV subretinal gene therapy for X‑linked retinitis pigmentosa and completed VISTA phase 3 enrollment in July.
- The 12‑month primary endpoint readout is expected before the end of 2026 and tests visual function improvements.